TP53 and P21 polymorphisms: Response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer
- 9 December 2005
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 340 (1) , 256-262
- https://doi.org/10.1016/j.bbrc.2005.11.176
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- The influence of HER2 genotypes as molecular markers in ovarian cancer outcomeBiochemical and Biophysical Research Communications, 2005
- A genetic variant in the gene encoding the stress70 protein chaperone family member STCH is associated with gastric cancer in the Japanese populationBiochemical and Biophysical Research Communications, 2005
- G-308A TNF-α polymorphism is associated with an increased risk of invasive cervical cancerBiochemical and Biophysical Research Communications, 2005
- Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in theTP53gene on survival in patients with advanced ovarian carcinomaHuman Mutation, 2004
- p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer1Gynecologic Oncology, 2004
- Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean womenGynecologic Oncology, 2004
- Metabolic susceptibility genes and prostate cancer risk in a southern European population: The role of glutathione S‐transferases GSTM1, GSTM3, and GSTT1 genetic polymorphismsThe Prostate, 2003
- Genetic analysis of benign ovarian tumorsInternational Journal of Cancer, 2003
- Mutant p53 protein expression interferes with p53-independent apoptotic pathwaysOncogene, 1998
- Polymorphisms in P21CIP1/WAF1 are not correlated with TP53 status in sporadic ovarian tumoursEuropean Journal Of Cancer, 1996